Syntax Bio, a Chicago biotech startup tucked into Fulton Market, says it has built a CRISPR-based "Cellgorithm" that can shrink the long, fussy process of coaxing stem cells into mature cell types from months down to days or weeks. In a newly released paper and press push, the company claims a single DNA "program" can flip the right genes on in sequence from inside the cell, cutting out many of the manual media changes that currently drag out lab protocols. If the approach holds up beyond the bench, it could speed work on stem-cell-derived therapies for diabetes, Parkinson’s disease, heart failure, and vision loss.
Science Advances paper lays out the method
The core method appears in a paper in Science Advances, where authors from Syntax Bio and collaborators describe a programmable, multistep CRISPR activation system tested in human induced pluripotent stem cells and other cell types. In the study, the team reports stepwise activation of transcription factors and lineage markers that usually take months to emerge under traditional differentiation protocols.
How Cellgorithm programs cells from the inside
The system hinges on so-called "proGuides," guide RNAs that are blocked by an RNA polymerase III terminator. Each proGuide becomes an active guide only after the preceding step removes that terminator, creating a built-in cascade of activations. In the setup, a Cas9-VPR fusion both converts proGuides into active guides and switches on endogenous genes in sequence, which removes many of the repeated hands-on interventions normally required, according to CRISPR Medicine News.
The company says the tech cuts weeks or months
Syntax Bio, which launched in 2024 and lists investors including Illumina Ventures and Astellas Venture Management, is pitching Cellgorithm as a way to "program" differentiation like software and speed both discovery and manufacturing. In a press release via Business Wire, the company said one internal collaboration cut a four-month protocol to under two weeks. CTO Ryan Clarke wrote, "We can now achieve an unprecedented level of temporal control over how genes turn on inside stem cells."
Based in Fulton Market, Chicago
Syntax Bio is headquartered at Portal Innovations' Fulton Labs in Chicago's Fulton Market and lists a Floor 9 address at 400 N. Aberdeen on its contact page. That spot places the startup in a growing cluster of life-science companies making use of shared wet-lab space and venture development services in the city, according to Portal Innovations.
Early results, real-world hurdles
Researchers note that the current demonstrations are strictly in vitro, and that turning programmable cascades into clinical-grade, reproducible manufacturing is a separate marathon. Both the study and outside commentators highlight practical challenges, such as pacing the cascades so they line up with the cell’s own rhythms and making sure the system behaves consistently across batches, issues discussed in the CRISPR Medicine News write-up.
For now, the paper hands other labs and biopharma partners a clear testable recipe: can sequential CRISPR-based instruction sets reliably make the right cells faster and at scale. Local coverage of the announcement appeared in Crain's Chicago Business, and Syntax Bio says it plans to pursue partnerships and continued preclinical work.
